0001839882-23-034399.txt : 20231221 0001839882-23-034399.hdr.sgml : 20231221 20231221123102 ACCESSION NUMBER: 0001839882-23-034399 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231215 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231221 DATE AS OF CHANGE: 20231221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DMK PHARMACEUTICALS Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 231504019 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Adamis Pharmaceuticals Corp DATE OF NAME CHANGE: 20090406 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 8-K 1 dmk-8k_121523.htm CURRENT REPORT
false 0000887247 0000887247 2023-12-15 2023-12-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM  8-K

 

     

 

CURRENT REPORT

 

     

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): December 15, 2023

 

     

 

DMK PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   0-26372   82-0429727
(State or other jurisdiction of
incorporation)		   (Commission File Number)   (IRS Employer Identification No.)

 

11622 El Camino Real, Suite 100

San Diego, CA

   92130
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 997-2400

 

(Former Name or Former Address, if Changed Since Last Report)

 

     

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
Common Stock   DMK   NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

 

 

Item 1.02 Termination of a Material Definitive Agreement.

 

Effective December 15, 2023, the distribution and commercialization contract between DMK Pharmaceuticals Corporation (the “Company”) and USWM, LLC (“US WorldMeds”) was terminated. US WorldMeds previously held exclusive distribution and commercialization rights for the Company’s SYMJEPI (epinephrine) and ZIMHI (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts. The distribution agreement between the Company and US WorldMeds previously was terminated as to the Company’s SYMJEPI products, and now is terminated as to the Company’s ZIMHI product, as well.

 

Item 8.01 Other Events

 

On December 21, 2023, the Company issued a press release regarding the termination of the US WorldMeds contract returning the rights to distribute and commercialize ZIMHI to the Company. A copy of the Company’s press release announcing this information and certain other information is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The information included in Item 2.02 (including Exhibit 99.1) of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit No. Description
99.1 Press Release issued December 21, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  DMK PHARMACEUTICALS CORPORATION
       
Dated: December 21, 2023 By: /s/ Seth A. Cohen  
  Name: Seth A. Cohen  
  Title: Chief Financial Officer  

 

2

 EX-99.1 2 ex99-1.htm PRESS RELEASE
 

DMK Pharmaceuticals Corporation 8-K

Exhibit 99.1

 

 

 

 

DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI

 

Company seeking commercialization partnerships in the United States,

Canada, and Europe to expand revenue generation

SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (Nasdaq: DMK) (“DMK”), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, announces that it has regained the full rights to commercialize ZIMHIÒ (naloxone) after the termination of an exclusive commercialization and distribution with US WorldMeds, LLC.

DMK is now actively seeking commercialization opportunities for ZIMHI, in the United States, Canada, and Europe, focused on new, near-term revenues. In the United States, first responders are the primary target for ZIMHI, where market data demonstrates significant, unmet demand.

Eboo Versi, M.D., Ph.D., DMK’s CEO commented, “I believe that ZIMHI is the ideal product for first responders because it acts so quickly to get patients breathing again to prevent death or prolonged hospitalization especially when faced with a fentanyl overdose. DMK is excited to engage with partners in the United States and abroad to drive long-term growth through new commercialization pathways. We will continue to execute an ambitious operating plan in the United States and expand our business relationships outside of the United States to maximize benefits to patients and DMK’s stakeholders, providing optimal shareholder value.”

About DMK Pharmaceuticals

DMK Pharmaceuticals is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders. DMK’s ZIMHI (naloxone) is FDA approved for the treatment of opioid overdose. DMK is focused on developing novel therapies for opioid use disorder (“OUD”) and other important neuro-based conditions where patients are currently underserved. DMK believes its technologies are at the forefront of endorphin-inspired drug design with its mono, bi-, and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. DMK believes that its library of approximately 750 small molecule neuropeptide analogues and differentiated pipeline can address significant unmet medical needs by integrating with the body’s own efforts to regain balance of disrupted physiology.

DMK’s lead clinical stage product candidate, DPI-125, is being studied as another potential and novel treatment for OUD. DMK also plans to develop the compound for the treatment of moderate to severe pain. DMK’s other development stage product candidates include DPI-221 for bladder-control problems and DPI-289 for severe end-stage Parkinson’s disease. For additional information about DMK Pharmaceuticals, please visit our website and follow us on Twitter and LinkedIn.

 

 
 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar words. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to anticipated future events or future results of operations, including, but not limited to, statements concerning (i) the ability of the Company to raise additional funds required to sustain the Company’s ongoing operations and fund the anticipated development activities regarding DPI-125, (ii) whether, if successfully developed, DPI-125 will receive a more favorable drug scheduling or be a more patient friendly treatment, (iii) the potential benefits of DPI-125 if successfully developed, and (iv) our ability to increase sales of our commercial products. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, which may cause the Company’s actual results to be materially different from the results anticipated by such forward-looking statements. These statements also assume that the Company will have or be able to obtain sufficient funding to support the activities described in this press release, continue the Company’s operations and satisfy the Company’s liabilities and obligations in a timely manner. There can be no assurance that this will be the case. Also, such statements assume that there are no significant unexpected developments or events that delay or prevent such activities from occurring. The Company will require additional funds to sustain operations, satisfy our obligations and liabilities, and fund its ongoing operations. There are no assurances that required funding will be available at all or will be available in sufficient amounts. Failure to timely obtain any required additional funding, or unexpected developments or events, could delay the occurrence of such events or prevent the events described in any such statements from occurring which could adversely affect our business, financial condition and results of operations. If we cannot continue as a viable entity, we might be required to reduce or cease operations or seek dissolution and liquidation or bankruptcy protection, and our stockholders would likely lose most or all of their investment in us. Accordingly, you should not rely upon forward-looking statements as predictions of future events. The Company cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks and additional risks, uncertainties, and other factors are described in greater detail in DMK’s filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2022, and subsequent filings with the SEC, which the Company strongly urges you to read and consider, all of which are available free of charge on the SEC’s website at http://www.sec.gov.

 

Investor and Media Contact:

investors@dmkpharma.com

 

 

Source: DMK Pharmaceuticals Corporation

 

 

 

 EX-101.SCH 3 dmk-20231215.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 dmk-20231215_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 dmk-20231215_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 dmk_001.jpg GRAPHIC begin 644 dmk_001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Dec. 15, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 15, 2023
Entity File Number 0-26372
Entity Registrant Name DMK PHARMACEUTICALS CORPORATION
Entity Central Index Key 0000887247
Entity Tax Identification Number 82-0429727
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 11622 El Camino Real
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 997-2400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol DMK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 dmk-8k_121523_htm.xml IDEA: XBRL DOCUMENT 0000887247 2023-12-15 2023-12-15 iso4217:USD shares iso4217:USD shares false 0000887247 8-K 2023-12-15 DMK PHARMACEUTICALS CORPORATION DE 0-26372 82-0429727 11622 El Camino Real Suite 100 San Diego CA 92130 (858) 997-2400 false false false false Common Stock DMK NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .%CE5<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #A8Y57I1UG"^\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>*';8'TSJ2\M.&PQ6V-C-V&IK&CO&UDCZ]DNR-F5L#["CI9\_ M?0(U)DK3)7Q)7<1$#O/-X-N0I8DK=B"*$B"; WJ=RS$1QN:N2U[3^$Q[B-H< M]1Y!5-4=>"1M-6F8@$5<^,.'-Z?GU[G=0L7 M,NE@&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #A8Y57NM\SSU4$ -$0 & 'AL+W=OLPWGFKS'49(-K(W6Z:UM9\&&QRR[EBE/ MX,A*JIAI&*JUG:6*LS /BB.;.D[;CIE(K&$_WS=5P[["1W \NUCCMF8KW19H<][*=LS>=<_TBG"D9VH1**F">9D E1?#6P//?VCMZ8 M@/R,/P3?92?;Q-S*4LI7,YB$ \LQ1#SB@382#'[>N,^CR"@!QS\'4:NXI@D\ MW3ZJW^S9!GW9?13A'HSL+H6"?F*;2,]D[OO_'!#.6 @HRS_)KO]N:V6 M18)MIF5\" :"6"3[7_9^2,1)0).>":"' )IS[R^44XZ89L.^DCNBS-F@9C;R M6\VC 4XDIBISK>"H@#@]].4;5WU;@Y3980>'L+M]&#T3-N+!-7%OK@AU:/._ MX380%!BTP*"Y7A/#(']YRTPK*-3?541[A5:U@NG>VRQE 1]8T)X95V_<&O[Z MB]MV?D/XF@5?$U,?CF2PA5[49/&1\BHX/+S;>$ @6@5$"U7Q@"#,*>XCMJZB MP.-7+,HXPG%3<-Q+BBEW:<%JTUZ$8GNN4[NE< CA) M JE2J7*V*S+7\#00J8@OMY!0R*L,*\M>HSX:8Y G%N]> NF%(1AC=G7<((]P M'GE)JLEP2==M4TK&$?$93$H26IQ%&&LY#[BHC>.LBYVL9,4EYUL!U7 =!P,L M)P(7M_+/@+X90:D7!KB<&5$X2+._QGN*(1ITJ^B22H+C6N MZ7L86CEGN+C5?T:;RDR#T_PITO-/!Z[8HVX3K6DY:;BXX^QX%%_C2 MO>E^Q5#*&J6'VXY*[BXB<]E) *A1;(F3]#@2GPVGP,/KE+'0\M9@.(^/56\ M$4!Z.#QA^U4B+-1@/?NR6E77KT:OEJRT?HK[]/_()EFV!;):0%RV%O!DW8^; M\T)H6*K)%7'IE^57,N?!%OJM$,VMV< ,=74NKCP+Q"%_^ #/\%4$L#!!0 ( .%CE5>? MH!OPL0( .(, - >&PO9KEMW MDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[< M9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20 MIV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/! M)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FS MX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5 M[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7S MJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41 MP+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS M#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U M(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT, M/O'^8* \^>Q\ETWLJ.?]74_P$4$L# M!!0 ( .%CE5>7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adamispharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports dmk-20231215.xsd dmk-20231215_lab.xml dmk-20231215_pre.xml dmk-8k_121523.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dmk-8k_121523.htm": { "nsprefix": "DMK", "nsuri": "http://adamispharmaceuticals.com/20231215", "dts": { "schema": { "local": [ "dmk-20231215.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "dmk-20231215_lab.xml" ] }, "presentationLink": { "local": [ "dmk-20231215_pre.xml" ] }, "inline": { "local": [ "dmk-8k_121523.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://adamispharmaceuticals.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "dmk-8k_121523.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "dmk-8k_121523.htm", "first": true, "unique": true } } }, "tag": { "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001839882-23-034399-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001839882-23-034399-xbrl.zip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�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